Doré et al.2 detected an overexpression of COX-2 in 56% of canine patients with mammary adenocarcinoma, suggesting that treatment with COX-2 inhibitors may be beneficial; and that COX-2 inhibitors reduce proliferation of neoplastic cells and may help to stall tumour growth3. The gene discussed is PTGS2; the disease is breast adenocarcinoma.